［1］Amini A，Byers LA，Welsh JW，et al.Progress in the management of limited-stage small cell lung cancer［J］.Cancer，2014，120(6)：790-798.
[2]Owonikoko TK，Behera M，Chen Z，et al.A systematic analysis of efficacy of second-line chemotherapy in sensitive and refractory smallcell lung cancer［J］.J Thorac Oncol，2012，7(5)：866-872.
[3]Kalemkerian GP，Schneider BJ.Advances in small cell lung cancer［J］.Hematol Oncol Clin N Am，2017，31(1)：143-156.
[4]Fink TH，Huber RM，Heigener DF，et al.Topotecan/cisplatin compared with cisplatin/etoposide as first-line treatment for patients with extensive disease small-cell lung cancer：Final results of a randomized phase III trial［J］.J Thorac Oncol，2012，7(9)：1432-1439.
[5]Satouchi M，Kotani Y，Shibata T，et al.Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive disease small-cell lung cancer：JCOG 0509［J］.J Clin Oncol，2014，32(12)：1262-1268.
[6]Von Pawel J，Jotte R，Spigel DR，et al.Randomized phase III trial of amrubicin topotecan as second-line treatment for patients with small cell lung cancer［J］.J Clin Oncol，2014，32(35)：4012-4019.
[7]Calvo E，Moreno V，Flynn M，et al.Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small cell lung cancer：Results from a phase I study［J］.Ann Oncol，2017，28(10)：2559-2566.
[8]Chen HB，Dy G，Groman A，et al.P1.07-001 a phase II study of etirinotecan pegol (NKTR-102)，a topoisomerase-I inhibitor polymer conjugate，in small cell lung cancer：Topic：Drug treatment alone and in combination with radiotherapy［J］.J Thorac Oncol，2017，12(1)：695-696.
[9]Tatematsu A，Shimizu J，Murakami Y，et al.Epidermal growth factor receptor mutations in small cell lung cancer［J］.Clin Cancer Res，2008，14(19)：6092-6096.
[10]Tanno S，Ohsaki Y，Nakanishi K，et al.Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib("Iressa"，ZD1839)［J］.Oncol Rep，2004，12(5)：1053-1057.
[11]Moore AM，Einhorn LH，Estes D，et al.Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers：A hoosier oncology group phase II trial［J］.Lung Cancer，2006，52(1)：93-97.
[12]Sequist LV，Waltman BA，Dias-Santagata D，et al.Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］.Sci Transl Med，2011，3(75)：75ra26.
[13]Spigel DR，Hainsworth JD，Simons L，et al.Irinotecan，carboplatin，and imatinib in untreated extensive-stage small-cell lung cancer：A phase II trial of the Minnie Pearl Cancer Research Network［J］.J Thorac Oncol，2007，2(9)：854-861.
[14]Schneider BJ，Kalemkerian GP，Ramnath N，et al.Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive，extensive-stage small-cell lung cancer［J］.Clin Lung Cancer，2010，11(4)：223-227.
[15]Miller AA，Pang H，Hodgson L，et al.A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (cancer and leukemia group B 30602)［J］.J Thorac Oncol，2010，5(3)：380-384.
[16]Ellis PM，Shepherd FA，Laurie SA，et al.NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer［J］.J Thorac Oncol，2014，9(3)：410-413.
[17]Belani CP，Dahlberg SE，Rudin CM，et al.Three-arm randomized phase II study of cisplatin and etoposide (CE) vs CE with either vismodegib (V) or cixitumumab (Cx) for patients with extensive-stage small cell lung cancer(ES-SCLC)(ECOG 1508)［J］.J Clin Oncol，2013，31(15)：460.
[18]George J，Lim JS，Jang SJ，et al.Comprehensive genomic profiles of small cell lung cancer［J］.Nature，2015，524(7563)：47-53.
[19]Sartorius UA，Krammer PH.Upregulation of BCL-2 is involved in the mediation ofchemotherapy resistance in human small cell lung cancer cell lines［J］.Int J Cancer，2002，97(5)：584-592.
[20]Faber AC，Farago AF，Costa C，et al.Assessment of ABT-263 activity across a cancercell line collection leads to a potent combination therapy for smallcelllung cancer［J］.Proceedings of the Naitonal Academy of Sciencesof the United States of America，2015，112(11)：1288-1296.
[21]Nakajima W，Sharma K，Hicks MA，et al.Combination with vorinostat overcomes ABT-263(navitoclax) resistance of small cell lung cancer［J］.Cancer Biol Ther，2016，17(1)：27-35.
[22]Sabari JK，Lok BH，Laird JH，et al.Unravelling the biology of SCLC：Implications for therapy［J］.Nat Rev Clin Oncol，2017，14(9)：549-561.
[23]Rudin CM，Pietanza MC，Bauer TM，et al.Rovalpituzumabtesirine，a DLL3-targeted antibody-drug conjugate，in recurrentsmall cell lung cancer：A first in human，first in class，open-label，phase 1 study［J］.Lancet Oncol，2017，18(1)：42-51.
[24]Tiseo M，Boni L，Ambrosio F，et al.Italian，multicenter，phase III，randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer：The GOIRC-AIFA FARM6PMFJM Trial［J］.J Clin Oncol，2017，35(12)：1281-1287.
[25]Li Q，Wu T，Jing L，et al.Angiogenesis inhibitors for the treatment of small cell lung cancer(SCLC)：A meta-analysis of 7 randomized controlled trials［J］.Medicine，2017，96(13)：e6412.
[26]Lu HY，Jiang ZM.Advances in antiangiogenic treatment of small-cell lung cancer［J］.Onco Targets Ther，2017，10：353-359.
[27]Ready NE，Pang HH，Gu L，et al.Chemotherapy with or without maintenance sunitinib for untreated extensive-stage small-cell lung cancer：A randomized，double-blind，placebo-controlled phase II study-CALGB 30504 (Alliance)［J］.J Clin Oncol，2015，33(15)：1660-1665.
[28]Sharma N，Pennell N，Nickolich M，et al.Phase II trial of sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer［J］.Invest New Drugs，2014，32(2)：362-368.
[29]Peng H，Zhang Q，Li J，et al.Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma［J］.Oncotarget，2016，7(13)：17220-17229.
[30]Zhao J，Zhang XL，Gong CJ，et al.Targeted therapy with apatinib in a patient with relapsed small cell lung cancer：A case report and literature review［J］.Medicine，2017，96 (50)：e9259.
[31]Hong W，Li H，Jin XY，et al.P1.07-053 apatinib for chemotherapy-refractory extensive stage SCLC：Results from a single-center retrospective study［J］.J Thorac Oncol，2017，12(1)：S729.
[32]Reck M，Bondarenko I，Luft A，et al.Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer：Results from a randomized，double-blind，multicenter phase 2 trial［J］.Ann Oncol，2013，24(1)：75-83.
[33]Reck M，Luft A，Szczesna A，et al.Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer［J］.J Clin Oncol，2016，34(31)：3740-3748.
[34]Wang A，Wang HY，Liu Y，et al.The prognostic value of PD-L1 expression for non- small cell lung cancer patients：A meta analysis［J］.Eur J Surg Oncol，2015，41(4)：450-456.
[35]Ishii H，Azuma K，Kawahara A，et al.Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer［J］.J Thorac Oncol，2015，10(3)：426-430.
[36]Ott PA，Hiret S，Kim D，et al.Pembrolizumab(MK3475) in patients with extensive-stage small cell lung cancer (SCLC)：Preliminary safety and efficacy results from KEYNOTE-028［J］.J Clin Oncol，2015，Suppl 33：a7502.
[37]Wang W，Lau R，Yu D，et al.PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+CD25(Hi) regulatory T cells［J］.Int Immunol，2009，21(9)：1065-1077.
[38]Hellmann MD，Antonia SJ，Ponce S，et al.Nivolumab alone or with ipilimumab in recurrent small cell lung cancer：2-year survival and updated analyses from the CheckMate 032 trial［J］.J Thorac Oncol，2017，12(1)：393-394.